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Granulocyte colony-stimulating factor (G-CSF) mobilizes peripheral blood stem cells (PBSCs) derived from 
bone marrow. We hypothesized that intraspinal transplantation of PBSCs mobilized by G-CSF could promote 
functional recovery after spinal cord injury. Spinal cords of adult nonobese diabetes/severe immunodefi-
ciency mice were injured using an Infinite Horizon impactor (60 kdyn). One week after the injury, 3.0 μl of 
G-CSF-mobilized human mononuclear cells (MNCs; 0.5 × 105/μl), G-CSF-mobilized human CD34-positive 
PBSCs (CD34; 0.5 × 105/μl), or normal saline was injected to the lesion epicenter. We performed immunohis-
tochemistry. Locomotor recovery was assessed by Basso Mouse Scale. The number of transplanted human 
cells decreased according to the time course. The CD31-positive area was significantly larger in the MNC 
and CD34 groups compared with the vehicle group. The number of serotonin-positive fibers was significantly 
larger in the MNC and CD34 groups than in the vehicle group. Immunohistochemistry revealed that the 
number of apoptotic oligodendrocytes was significantly smaller in cell-transplanted groups, and the areas of 
demyelination in the MNC- and CD34-transplanted mice were smaller than that in the vehicle group, indicat-
ing that cell transplantation suppressed oligodendrocyte apoptosis and demyelination. Both the MNC and 
CD34 groups showed significantly better hindlimb functional recovery compared with the vehicle group. 
There was no significant difference between the two types of transplanted cells. Intraspinal transplantation 
of G-CSF-mobilized MNCs or CD34-positive cells promoted angiogenesis, serotonergic fiber regeneration/
sparing, and preservation of myelin, resulting in improved hindlimb function after spinal cord injury in com-
parison with vehicle-treated control mice. Transplantation of G-CSF-mobilized PBSCs has advantages for 
treatment of spinal cord injury in the ethical and immunological viewpoints, although further exploration is 
needed to move forward to clinical application.
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INTRODUCTION
The central nervous system, including the spinal cord, 
is a delicate tissue that cannot tolerate damaging physio-
logical conditions. Thus, poor recovery following injury 
is generally attributed to the hostile local milieu created 
at the site of injury. Spinal cord injury (SCI) is character-
ized by so-called secondary injuries that are triggered by 
the initial mechanical insult (29). These include hemor-
rhage, destruction of the blood–spinal cord barrier, and 
infiltration of inflammatory cells. The damage is medi-
ated by a complex cascade of deleterious events that 
lead to further degenerative damage, including spinal 
cord ischemia beyond the site of initial injury (8). Those 
events suggest that angiogenesis-promoting treatments 
might be valuable for SCI treatment in both the acute 
and subacute phases.
Granulocyte colony-stimulating factor (G-CSF) is a 
19.6-kDa glycoprotein that is best known as a growth 
factor for hematopoietic progenitor cells. It is clinically 
used to treat neutropenia and to mobilize peripheral 
blood-derived hematopoietic stem cells for transplanta-
tion (20,24). Furthermore, G-CSF mobilizes peripheral 
blood stem cells (PBSCs) derived from bone marrow. 
The mobilized PBSCs reach the injured spinal cord by 
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migrating through the disrupted blood–spinal cord bar-
rier. However, only modest numbers of mobilized PBSCs 
reach the site of spinal cord injury (17). Thus, we hypoth-
esized that intraspinal transplantation of PBSCs mobi-
lized by G-CSF could promote better functional recovery 
after contusive SCI.
In the current study, we tested whether intraspinal 
transplantation of human G-CSF-mobilized mononuclear 
cells or CD34-positive PBSCs promote angiogenesis and 
accelerate hindlimb functional recovery in mouse contu-
sive SCI.
MATERIALS AND METHODS
All experimental procedures were performed in accor-
dance with the Chiba University School of Medicine 
guidelines pertaining to the treatment of experimental 
animals. The approval of the Animal Committee of Chiba 
University Graduate School of Medicine was obtained 
before we started the experiments (the approval number 
was 25-72).
Spinal Cord Injury
A total of 48 adult female nonobese diabetes/severe 
immunodeficiency (NOD/SCID) mice (8 to 9 weeks old, 
average weight 25 g; Charles River Japan, Yokohama, 
Japan) were used in this study. Animals were anesthetized 
with inhaled 1.0–1.2% halothane (Wako, Osaka, Japan) 
in 0.5 L/min oxygen. Laminectomy was performed at 
the thoracic (T) 9 vertebral level, leaving the dura intact. 
The T8 and T10 spinous processes of the vertebra were 
clamped to fix the spine. Then their spinal cords were 
injured using an Infinite Horizon impactor (60 kdyn; 
Precision Systems and Instrumentation, Lexington, KY, 
USA). After that, muscles and skin were sutured layer 
to layer, and the mice were placed in warm cages over-
night. Food and water were given ad libitum. All animals 
were given saline with antibiotics (Cefmetazon; Daiichi-
Sankyo Pharmaceuticals, Tokyo, Japan) by subcutaneous 
administration to avoid dehydration and infection once a 
day for 3 days. Manual bladder expression was performed 
twice a day until recovery of the bladder reflex.
Cell Transplantation
One week after the initial injury, the mice were ran-
domly allocated to three groups, and the spinal cords 
were reexposed. In the mononuclear cell (MNC) group 
(n = 16), 3.0 μl of G-CSF-mobilized human MNCs 
(0.5 × 105/μl) was injected into the lesion site with a fine 
glass pipette attached to a Hamilton syringe (Hamilton 
Company, Reno, NV, USA). In the CD34-positive group 
(n = 16), 3.0 μl of G-CSF-mobilized human CD34-postive 
PBSC (0.5 × 105/μl) were injected into the lesion site. The 
cell dosage was determined according to the previous 
studies (16,18).
In the vehicle group (n = 16), normal saline (3.0 μl) was 
injected in the same fashion as the transplanted groups. 
We purchased human cells mobilized by G-CSF (MNC: 
mPB004F; CD34-positive PBSCs: mPB015F; All Cells, 
Alameda, CA, USA). The injection speed was set to 
1 μl/min for each group with an air-driven syringe pump 
(PUMP 11 ELITE; Harvard Apparatus, Holliston, MA, 
USA). After surgery, animals were treated the same way 
as after the initial surgery.
Tissue Preparation
Mice were sacrificed 1 week (n = 3/group), 3 weeks 
(n = 3/group), and 7 weeks (after the termination of loco-
motor assessment, n = 10/group) after the transplantation. 
The animals were deeply anesthetized with intraperito-
neal sodium pentobarbital (Kyoritsu Seiyaku, Tokyo, 
Japan) and perfused transcardially with 4% paraformal-
dehyde (Wako) in phosphate-buffered saline (PBS, pH 
7.4; Life Technologies Japan, Tokyo, Japan). Spinal cords 
including the lesion site were removed and postfixed in 
the same fixative for 24 h. Then tissues were immersed 
in 20% sucrose in PBS at 4°C. After that, the tissue 
was embedded in OCT compound (Tissue-Tek, Sakura 
Finetech. Tokyo, Japan), frozen on dry ice, and sectioned 
on a cryostat. The sagittal serial frozen spinal cord sec-
tions (25 μm in thickness) were mounted onto poly-l-
lysine-coated glass slides (Matsunami, Tokyo, Japan). 
Each slide contained five sliced sections at 100-μm inter-
vals, and the sections for each slide were offset by 25 μm 
from the previous slide in the set. In this way, we were 
able to cover the central 500 μm of the lesion at 25-μm 
intervals in five slides.
Immunohistochemistry
We performed immunohistochemistry as previously 
described (7,11). Sections of mouse spinal cord were 
rehydrated with 0.3% Triton-X (Wako) in PBS for 1 h and 
washed three times with PBS. Slides were then incubated 
with blocking solution (Block Ace; Yukijirushi, Sapporo, 
Japan) for 1 h at room temperature. The primary antibod-
ies were as follows: mouse monoclonal anti-human mito-
chondria antibody (1:100; Merck Millipore, Billerica, 
MA, USA), which is a marker for transplanted human 
cells; mouse anti-myelin basic protein (1:400; Merck 
Millipore), which is a marker for residual myelin sheath, 
and rat monoclonal anti-CD31 antibody (CD31, 1:400; 
Merck Millipore), which is a marker for endothelial 
cells of murine and human origin. Double immunofluo-
rescence for cleaved caspase 3 (1:400; R&D Systems, 
Minneapolis, MN, USA), which is a marker for apoptotic 
cells, and adenomatous polyposis coli (APC, clone CC-1, 
1:800, Merck Millipore), which is a marker for oligoden-
drocyte, was performed to evaluate the effect of cell trans-
plantation on apoptosis. To assess axonal regeneration/
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sparing, immunohistochemistry for serotonin and growth- 
associated protein-43 (GAP-43) was performed using 
rabbit anti-serotonin polyclonal antibody (1:800, S5545; 
Sigma-Aldrich, St. Louis, MO, USA) and mouse anti- 
GAP-43 monoclonal antibody (1:400; Abcam, Cam-
bridge, UK). Serotonergic fibers have been previously 
reported to contribute to hindlimb motor control in 
rodents (4,6,25). The sections were reacted overnight at 
4°C. After three 10-min washes with PBS, the sections 
were reacted with Alexa Fluor 488-conjugated or Alexa 
Fluor 594-conjugated donkey anti-mouse IgG (1:800; 
Life Technologies, Carlsbad, CA, USA) and with Alexa 
Fluor 488-conjugated or Alexa Fluor 594-conjugated 
goat anti-rabbit IgG (1:800; Life Technologies).
Quantification
Quantification of histological and immunohistochem-
ical results was performed by blinded observers kept 
unaware of treatment groups. The numbers of transplanted 
cells were counted in the lesion epicenter as human mito-
chondria-positive cells. MBP-negative area, which indi-
cates the degree of tissue destruction, was measured with 
ImageJ software and expressed as the ratio to the total 
white matter area. CD31- and serotonin-positive areas 
were measured by ImageJ software and were expressed 
as the ratio of those immunopositive areas to the total spi-
nal cord area observed. The number of double-positive 
cells for cleaved caspase 3 and CC-1, which indicates the 
number of apoptotic oligodendrocytes, was counted.
Locomotor Function and Behavioral Testing
Hindlimb functional recovery was assessed using the 
Basso Mouse Scale (BMS) (2). Mice were observed indi-
vidually for 5 min each in an open field by two blinded 
investigators. Hindlimb motor function was recorded and 
scored according to the BMS guidelines once per week. 
All open-field BMS score episodes were recorded using 
a video camera and were reviewed later to confirm the 
accuracy. We followed the BMS score for 8 weeks after 
the transplantation (n = 10 per group). After 8 weeks, we 
performed movement analysis using the SCANET MV-40 
(Melquest, Toyama, Japan) (Fig. 6B). The mice were 
allowed to move freely in the attached wide plastic box. 
The SCANET system consists of a cage equipped with 
two crossing infrared sensor frames arranged at different 
heights, with which small (M1) and large (M2) horizontal 
Figure 1. Transplanted peripheral mononuclear cells (MNCs) or CD34-positive cells mobilized by granulocyte colony-stimulating 
factor survived in injured spinal cord. Survived CD34-positive cells were located around the epicenter (A, B). MNC and CD34-positive 
cells were stained with anti-human mitochondria antibody. The number of transplanted cells decreased over time (C). Scale bars: 1 mm 
(A) and 100 mm (B). Asterisks indicates significant difference between 2, 4, and 8 weeks after the injury (*p < 0.05, **p < 0.01, C).
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movements were monitored. We assessed locomotor 
function by determining the M1 scores for 30 min. The 
quantity of motions was analyzed automatically (19).
Statistical Analysis
The results were evaluated by multiple comparisons 
among control, mononuclear, and CD34 groups. BMS 
scores were analyzed by repeated-measures analysis of 
variance (ANOVA) followed by the post hoc Tukey–
Kramer test. The amounts of spontaneous motion mea-
sured by the SCANET-40 as well as immunohistochemical 
data were subjected to ANOVA. Data are presented as 
mean values ± standard errors of the mean (SEM). Dif-
ferences were considered as significant at p < 0.05.
RESULTS
Immunohistochemical analyses of injured spinal cords 
were conducted 1, 3, and 7 weeks after the transplanta-
tion [2 weeks (n = 3/group), 4 weeks (n = 3/group), and 
8 weeks (n = 10/group) after the injury]. We assessed the 
frequency and distribution of transplanted human mito-
chondria-positive cells. One week after the transplanta-
tion (2 weeks after the injury, transplanted human cells 
were detected in segments 2 mm rostral and 2 mm cau-
dal to the lesion site in both the MNC and CD34 groups) 
(Fig. 1A, B). There was no significant difference between 
the numbers of detected human cells in the two groups. 
Three weeks after the transplantation (4 weeks after the 
injury), the numbers of transplanted cells significantly 
decreased in both groups (Fig. 1C). No transplanted 
human cell was detected 7 weeks after the transplantation 
(8 weeks after the injury) (Fig. 1C).
We measured the CD31-positive area at the lesion epi-
center, an indicator of neovascularization, and compared 
the results among the three treatment groups. The CD31-
positive area was significantly larger in the MNC and 
CD34 groups compared with the vehicle group (Fig. 2). 
There was no significant difference between the MNC 
Figure 2. Transplantation of peripheral mononuclear cells (MNCs) or CD34-positive cells mobilized by granulocyte colony-stimulating 
factor promoted angiogenesis in injured spinal cord. CD31-positive area around the injury epicenter was larger in both the cell-transplanted 
groups compared with that in the vehicle group (G). There was no significant difference between the MNC and CD34 groups. Scale bars: 
1 mm (A–C) and 100 mm (D–F). Asterisks indicate significant difference compared with the vehicle group (**p < 0.01, G).
G-CSF-MOBILIZED PERIPHERAL BLOOD STEM CELLS FOR SCI 287
and CD34 groups in the CD31-positive area (Fig. 2B, C, 
E F, –G). We carried out immunohistochemical analy-
sis for serotonin, a marker for raphe-spinal serotonergic 
fibers that constitute important tracts for hindlimb motor 
control. The data revealed that the area of serotonin-posi-
tive fibers was significantly larger in the MNC and CD34 
groups than in the vehicle group at the rostral and caudal 
segments (Fig. 3A–G). The serotonin-positive area at the 
lesion epicenter was larger in the CD34 group compared 
with that in the vehicle group, whereas there was no sig-
nificant difference between the MNC and the vehicle 
group (Fig. 3G). Moreover, a part of those serotonin-
positive fibers was also positive for GAP-43, which is 
a marker for growth cone indicating regenerating axons 
(Fig. 3H–J). We performed double immunofluorescence 
study for cleaved caspase 3 (a marker for apoptotic cells) 
and CC-1 (a marker for oligodendrocytes) to assess the 
effect for cell transplantation on apoptosis of oligoden-
drocytes. The number of double-positive cells for cleaved 
caspase 3 and CC-1 was significantly larger in the MNC 
and CD34 groups than that in the vehicle group (Fig. 4). 
We used immunohistochemistry for MBP to investi-
gate the area of the demyelinated sheath 7 weeks after 
transplantation (8 weeks after the injury, n = 4/group). 
Immunohistochemistry for MBP revealed that the areas 
of demyelination in the MNC- and CD34-transplanted 
mice was significantly smaller than that in the vehicle 
group, indicating that cell transplantation suppressed 
demyelination (Fig. 5A–D).
Both the MNC and CD34 groups showed signifi-
cantly better hindlimb functional recovery compared 
with the vehicle group (repeated measures ANOVA, 
p < 0.01) (Fig. 6A). Post hoc analysis revealed signifi-
cant increase of the BMS score 6 to 8 weeks after the 
initial injury in the MNC and CD34 groups compared 
with the vehicle group (p < 0.01) (Fig. 6A). There was 
no significant difference between the two types of trans-
planted cells. The recovered BMS score in cell-trans-
planted groups was approximately six points, which 
indicates “frequent or consistent plantar stepping, some 
coordination, paws parallel at initial contact” or “fre-
quent or consistent plantar stepping, mostly coordinated, 
paws rotated at initial contact and liftoff,” whereas the 
recovered BMS score in the vehicle group was approxi-
mately five points, which indicates “frequent or consis-
tent plantar stepping, no coordination” or “frequent or 
consistent plantar stepping, some coordination, paws 
rotated at initial contact and liftoff.” Those differences 
of BMS scores between the cell-transplanted groups 
and the vehicle group are simulated to the capability of 
weight bearing in clinical situations.
We also assessed the quantity of spontaneous locomo-
tion with the SCANET MV-40 8 weeks after the injury. 
A significant increase in the quantity of locomotion in the 
CD34 group was detected compared with the vehicle group 
(p < 0.01) (Fig. 6B, C), whereas the MNC group showed no 
significant increase in spontaneous locomotion.
DISCUSSION
In this study, we examined the impact of intraspinal 
transplantation of G-CSF-mobilized enriched human 
CD34-positive cells or mononuclear cells following SCI 
in mice. The data demonstrated that 7 weeks after treat-
ment (8 weeks after the injury) intraspinal transplantation 
promoted angiogenesis, serotonergic fiber regeneration/
sparing, suppression of oligodendrocyte apoptosis, and 
preservation of myelin, resulting in improved hindlimb 
function after SCI in comparison with vehicle-treated 
control mice.
The various cell types that make up the blood are 
of mesodermal origin and are derived from a common 
pool of PBSCs. During embryogenesis, hematopoietic 
and endothelial lineage cells are derived from common 
progenitor cells, called hemangioblasts. In adult humans, 
CD34-positive cells likely include the PBSC fraction, and 
they have been used clinically for hematopoietic stem cell 
transplantation and reconstitution. After G-CSF adminis-
tration, leukocytes, including CD34-positive PBSCs, are 
mobilized from bone marrow, and they can be readily 
collected by apheresis (9). Recently, human peripheral 
blood CD34-positive cells were reported to include an 
endothelial progenitor cell-enriched population as well as 
a PBSC fraction (1). Thus, intravenous administration of 
G-CSF mobilized CD34-positive PBSCs has been shown 
to facilitate vascular regeneration of ischemic tissues, and 
therapeutic use of CD34-positive PBSC transplantation 
for ischemic tissue has been performed in many preclini-
cal studies (10,12,26,27). In patients with ischemic dis-
eases of lower limbs, transplanted PBSC mobilized by 
G-CSF are capable of enhancing neovascularization. In 
patients with acute myocardial infarction, transplanta-
tion of CD34-positive cells promotes vasculogenesis 
and cardiomyogenesis, enhancing functional regenera-
tive recovery (10,15). Furthermore, in a cerebral stroke 
model, intracerebral CD34-positive PBSC implantation 
has enhanced neovascularization in the penumbra region 
of the ischemic brain and subsequently promoted marked 
neurogenesis (3, 26).
In SCI, the use of hematopoietic stem cells derived 
from human umbilical cord blood was reported to pro-
mote restoration of spinal cord tissue and recovery of 
hindlimb function in adult rats (21,23). Human umbili-
cal cord blood-derived CD34-positive cells were also 
beneficial in restoring hindlimb function by stimulating 
production of glial cell line-derived neurotrophic factor 
(GDNF) and vascular endothelial growth factor (VEGF) 
(13). We have demonstrated that intraspinal transplan-
tation of human CD34-positive PBSCs mobilized by 
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Figure 3. Transplantation of peripheral mononuclear cells (MNCs) or CD34-positive cells mobilized by granulocyte colony-stimulating 
factor promoted serotonergic axonal regeneration/sparing in injured spinal cord. More serotonin-positive axons were observed in the 
segment rostral to the injury epicenter in both the cell-transplanted groups (A–F). Serotonin-positive area in the segments rostral and 
caudal to the injury epicenter was larger in both the cell-transplanted groups compared with that in the vehicle group (G). In the lesion 
epicenter, CD34 group showed significantly larger serotonin-positive area compared with that in the vehicle group, whereas there was 
no significant difference between the MNC and vehicle groups (G). There was no significant difference in serotonin-positive area 
between the MNC and CD34 groups (G). Double immunofluorescence study revealed a part of those serotonergic fibers was also posi-
tive for growth-associated protein-43 (a marker for regenerating axons, H–J). Scale bars: 1 mm (A–C), 100 mm (D–F, H–J). Asterisks 
indicate significant difference compared with the vehicle group (**p < 0.01, *p < 0.05).
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G-CSF promoted angiogenesis in injured spinal cord 
and functional recovery in mice. Mononuclear cells col-
lected following G-CSF treatment include many cell 
populations in addition to CD34-positive cells, including 
CD45-, CD133-, and CD11b-positive cells. The present 
results showed that there was no significant difference 
between MNC and CD34-positive groups in promotion of 
Figure 4. Transplantation of MNC and CD34 suppressed oligodendrocytre apoptosis. Double immunofluorescence study revealed 
that the number of double-positive cells for cleaved caspase 3 (a marker for apoptotic cells) and CC-1 (a marker for oligodendrocytes), 
which indicates apoptotic oligodendrocytes, was smaller in the MNC and CD34 groups than that in the vehicle group. Scale bar: 50 mm 
(A–I). Arrows indicate double-positive cells for cleaved caspase 3 and CC-1. Asterisks indicate significant difference compared with 
the vehicle group (*p < 0.05).
angiogenesis, axonal regeneration/sparing, tissue restora-
tion, and hindlimb functional recovery, although the total 
MNC fraction contained a small number of CD34-positive 
hematopoietic stem cell/endothelial progenitor cells.
It has been reported that the G-CSF-mobilized MNC 
fraction is capable of neovascular regeneration in the 
ischemic brain (26). As for the spinal cord, recent reports 
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have indicated that the G-CSF-mobilized MNC fraction 
can promote angiogenesis and has therapeutic effects in 
SCI (5), indicating that other cell populations than CD34-
positive cells can promote neurological recovery.
The possible underlying mechanisms of action of MNC 
and CD34-positive cell transplantation are as follows. The 
results of immunohistochemistry for human cell markers 
showed that transplanted MNC and CD34-positive cells 
disappeared 4 weeks after injury. In spite of the poor sur-
vival of transplanted cells, angiogenesis, axonal regener-
ation/sparing, and tissue preservation were observed at a 
final follow-up time point 8 weeks after injury. A double 
immunofluorescence study revealed antiapoptotic effect 
and serotonergic axonal regeneration-promoting effect 
of those types of cell transplantation. These data suggest 
that the transplanted cells exert their therapeutic potential 
through early effector mechanisms, including secretion 
of soluble factors and immunomodulation.
We previously reported that intravenous injection 
of G-CSF mobilized bone marrow-derived cells to the 
injured spinal cord directly suppressed neuronal apopto-
sis and promoted angiogenesis in the injured spinal cord 
(14,17,22). We have completed an early phase clinical trial 
of neuroprotective therapy using intravenous injection of 
G-CSF for patients with acute SCI (28). In the present 
study, we demonstrated possible therapeutic effects of 
MNC and CD34-positive PBSC intraspinal transplanta-
tion. We suspect that a combination therapy of intravenous 
G-CSF injection in the acute phase to protect spinal cord 
tissue from secondary injury mechanisms and intraspi-
nal transplantation of MNC and CD34-positive PBSCs 
mobilized by G-CSF injection in the subacute phase 
could improve motor and sensory function in patients 
with acute SCI. G-CSF is clinically used to treat hema-
tological disorders and is essentially safe, and autologous 
PBSC transplantation can be performed without problems 
of immune rejection. Moreover, G-CSF-mobilized PBSC 
transplantation is less problematic because there are no 
major ethical concerns arising from the use of embryonic 
tissues as a cell source.
In conclusion, transplantation of G-CSF-mobilized 
peripheral MNCs or CD34-positive cells is a realistic 
approach for treatment of SCI in ethical and immunologi-
cal viewpoints, although further exploration is needed to 
move forward to clinical application.
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Figure 5. Transplantation of peripheral mononuclear cells (MNCs) or CD34-positive cells mobilized by granulocyte colony- 
stimulating factor promoted tissue sparing in injured spinal cord. Myelin basic protein-negative area, which indicates demyelination, 
was smaller in both the cell transplanted groups compared with that in the vehicle group (A–D). There was no significant difference 
between the MNC and CD34 groups. Scale bar: 1 mm (A–C). Asterisks indicate significant difference compared with the vehicle 
group (*p < 0.05, D).
G-CSF-MOBILIZED PERIPHERAL BLOOD STEM CELLS FOR SCI 291
REFERENCES
Asahara, T.; Murohara, T.; Sullivan, A.; Silver, M.; van der  1. 
Zee, R.; Li, T.; Witzenbichler, B.; Schatteman, G.; Isner, 
J. M. Isolation of putative progenitor endothelial cells for 
angiogenesis. Science 275:965–967; 1997.
Basso, D. M.; Beattie, M. S.; Bresnahan, J. C. A sensitive  2. 
and reliable locomotor rating scale of open field testing in 
rats. J. Neurotrauma 12:1–21; 1995.
Boy, S.; Sauerbruch, S.; Kraemer, M.; Schormann, T.;  3. 
Schlachetzki, F.; Schuierer, G.; Luerding, R.; Hennemann, 
B.; Orso, E.; Dabringhaus, A.; Winkler, J.; Bogdahn, U.; R. A. 
I. S. (Regeneration in Acute Ischemic Stroke) Study Group. 
Mobilisation of hematopoietic CD34+ precursor cells in 
patients with acute stroke is safe - Results of an open-labeled 
non randomized phase I/II trial. PLoS One 6:e23099; 2011.
Bregman, B. S.; Kunkel-Bagden, E.; Reier, P. J.; Dai, H.  4. 
N.; McAtee, M.; Gao, D. Recovery of function after spinal 
cord injury: Mechanisms underlying transplant-mediated 
recovery of function differ after spinal cord injury in new-
born and adult rats. Exp. Neurol. 123:3–16; 1993.
Carvalho, K. A.; Vialle, E. N.; Moreira, G. H.; Cunha, R.  5. 
C.; Simeoni, R. B.; Francisco, J. C.; Guarita-Souza, L. C.; 
Figure 6. Transplantation of peripheral mononuclear cells (MNCs) or CD34-positive cells mobilized by granulocyte colony-stimulating 
factor promoted hindlimb functional recovery after spinal cord injury. Locomotor function was assessed using Basso Mouse Scale (BMS). 
Repeated measures ANOVA and post hoc test showed better functional recovery in both the cell transplantation groups (A, square: MNC, 
triangle: CD34) than the vehicle group (A, circle). Spontaneous movement was measured by SCANET-40Ò (B). CD34 group showed 
significant increase of spontaneous movement compared with that in the other groups (C). Values are mean ± SEM. **p < 0.01 (A, C).
292 TAKAHASHI ET AL.
Oliveira, L.; Zocche, L.; Oladoski, M. Functional outcome 
of bone marrow stem cells (CD45+/CD34-) after cell ther-
apy in chronic spinal cord injury in Wistar rats. Transplant. 
Proc. 40:845–846; 2008.
Deumens, R.; Koopmans, G. C.; Joosten, E. A. Regeneration  6. 
of descending axon tracts after spinal cord injury. Prog. 
Neurobiol. 77:57–89; 2005.
Hashimoto, M.; Koda, M.; Ino, H.; Murakami, M.;  7. 
Yamazaki, M.; Moriya, H. Upregulation of osteopon-
tin expression in rat spinal cord microglia after traumatic 
injury. J. Neurotrauma 20:287–296; 2003.
Hausmann, O. N. Post-traumatic inflammation following  8. 
spinal cord injury. Spinal Cord 41:369–378; 2003.
Henschler, R.; Brugger, W.; Luft, T.; Frey, T.; Mertelsmann,  9. 
T.; Kanz, L. Maintenance of transplantation potential in ex 
vivo expanded CD34(+)-selected human peripheral blood 
progenitor cells. Blood 84:2898–2903; 1994. 
Iwasaki, H.; Kawamoto, A.; Ishikawa, M.; Oyamada, A.; 10. 
Nakamori, S.; Nishimura, H.; Sadamoto, K.; Horii, M.; 
Matsumoto, T.; Murasawa, S.; Shibata, T.; Suehiro, S.; 
Asahara, T. Dose-dependent contribution of CD34-positive 
cell transplantation to concurrent vasculogenesis and car-
diomyogenesis for functional regenerative recovery after 
myocardial infarction. Circulation 113:1311–1325; 2006. 
Kamada, T.; Koda, M.; Dezawa, M.; Yoshinaga, K.; 11. 
Hashimoto, M.; Koshizuka, S.; Nishio, Y.; Moriya, H.; 
Yamazaki, M. Transplantation of bone marrow stromal 
cell-derived Schwann cells promotes axonal regeneration 
and functional recovery after complete transection of adult 
rat spinal cord. J. Neuropathol. Exp. Neurol. 64:37–45; 
2005. 
Kalka, C.; Masuda, H.; Takahashi, T.; Kalka-Moll, W. M.; 12. 
Silver, M.; Kearney, M.; Li, T.; Isner, J. M.; Asahara, T. 
Transplantation of ex vivo expanded endothelial progenitor 
cells for therapeutic neovascularization. Proc. Natl. Acad. 
Sci. USA 97:3422–3427; 2000. 
Kao, C. H.; Chen, S. H.; Chio, C. C.; Lin, M. T. Human 13. 
umbilical cord blood-derived CD34+ cells may attenuate 
spinal cord injury by stimulating vascular endothelial and 
neurotrophic factors. Shock 29:49–55; 2008. 
Kawabe, J.; Koda, M.; Hashimoto, M.; Fujiyoshi, T.; Furuya, 14. 
T.; Endo, T.; Okawa, A.; Yamazaki, M. Neuroprotective 
effects of granulocyte colony-stimulating factor and rela-
tionship to promotion of angiogenesis after spinal cord 
injury in rats: Laboratory investigation. J. Neurosurg. Spine 
15:414–421; 2011.
Kocher, A. A; Schuster, M. D.; Szabolcs, M. J.; Takuma, 15. 
S.; Burkhoff, D.; Wang, J.; Homma, S.; Edwards, N. M.; 
Itescu, S. Neovascularization of ischemic myocardium by 
human bone-marrow-derived angioblasts prevents cardio-
myocyte apotosis, reduces remodeling and improves car-
diac function. Nat. Med. 7:430–436; 2001.
Koda, M.; Okada, S.; Nakayama, T.; Koshizuka, S.; 16. 
Kamada, T.; Nishio, Y.; Someya, Y.; Yoshinaga, K.; Okawa, 
A.; Moriya, H.; Yamazaki, M. Hematopoietic stem cell 
and marrow stromal cell for spinal cord injury in mice. 
Neuroreport 16:1763–1767; 2005.
Koda, M.; Nishio, Y.; Kamada, T.; Someya, Y.; Okawa, A.; 17. 
Mori, C.; Yoshinaga, K.; Okada, S.; Moriya, H.; Yamazaki, 
M. Granulocyte colony-stimulating factor (G-CSF) mobi-
lizes bone marrow-derived cells into injured spinal cord 
and promotes functional recovery after compression-in-
duced spinal cord injury in mice. Brain Res. 1149:223–231; 
2007.
Mannoji, C.; Koda, M.; Dezawa, M.; Hashimoto, M.; 18. 
Furuya, T.; Okawa, A.; Takahashi, K.; Yamazaki, M. 
Transplantation of human bone marrow stromal cell-de-
rived neuroregenerative cells promotes functional recov-
ery after spinal cord injury in mice. Acta. Neurobiol. Exp. 
74:479–488; 2014.
Mikami, Y.; Toda, M.; Watanabe, M.; Nakamura, M.; 19. 
Toyama, Y.; Kawakami, Y. A simple and reliable behavioral 
analysis of locomotor function after spinal cord injury in 
mice. Technical note. J. Neurosurg. 9:142–147; 2002.
Nicola, N. A.; Metcalf, D.; Matsumoto, M.; Johnson, G. R. 20. 
Purification of a factor inducing differentiation in murine 
myelomonocytic leukemia cells. Identification as granulo-
cyte colony-stimulating factor. J. Biol. Chem. 258:9017–
9123; 1983.
Nishio, Y.; Koda, M.; Kamada, T.; Someya, Y.; Kadota, R.; 21. 
Mannoji, C.; Miyashita, T.; Okada, S.; Okawa, A.; Moriya, 
H.; Yamazaki, M. Granulocyte colony-stimulating factor 
attenuates neuronal death and promotes functional recov-
ery after spinal cord injury in mice. J. Neuropathol. Exp. 
Neurol. 66:724–31; 2007. 
Nishio, Y.; Koda, M.; Kamada, T.; Someya, Y.; Yoshinaga, 22. 
K.; Okada, S.; Harada, H.; Okawa, A.; Moriya, H.; 
Yamazaki, M. The use of hemopoietic stem cells derived 
from human umbilical cord blood to promote restoration 
of spinal cord tissue and recovery of hindlimb function in 
adult rats. J. Neurosurg. Spine 5:424–433; 2006.
Ozdemir M.; Attar A.; Kuzu I. Regenerative treatment in 23. 
spinal cord injury. Curr. Stem Cell Res. Ther. 7:364–369; 
2012.
Roberts, A. W. G-CSF (Granulocyte colony-stimulating 24. 
factor): A key regulator of neutrophil production, but that’s 
not all! Growth Factors 23:33–41; 2005.
Shapovalov, A. I. Neuronal organization and synaptic 25. 
mechanisms of supraspinal motor control in vertebrates. 
Rev. Physiol. Biochem. Pharmacol. 72:1–54; 1975.
Shyu, W. C.; Lin, S. Z.; Chian, M. F.; Su, C. Y.; Li, H. 26. 
Intracerebral peripheral blood stem cell (CD34+) implan-
tation induces neuroplasticity by enhancing b1 integrin-
mediated angiogenesis in chronic stroke rats. J. Neurosci. 
26:3444–3453; 2006. 
Taguchi, A.; Soma, T.; Tanaka, H.; Kanda, T.; Nishimura, 27. 
H.; Yoshikawa, H.; Tsukamoto, Y.; Iso, H.; Fujimori, Y.; 
Stern, D. M.; Naritomi, H.; Matsuyama, T. Administration 
of CD34+ cells after stroke enhances neurogenesis via 
angiogenesis in a mouse model. J. Clin. Invest. 114:330–
338; 2004.
Takahashi, H.; Yamazaki, M.; Okawa, A.; Sakuma, T.; Kato, 28. 
K.; Hashimoto, M.; Hayashi, K.; Furuya, T.; Fujiyoshi, 
T.; Kawabe, J.; Yamauchi, T.; Mannoji, C.; Miyashita, T.; 
Kadota, R.; Hashimoto, M.; Ito, Y.; Takahashi, K.; Koda, 
M. Neuroprotective therapy using granulocyte colony-
stimulating factor for acute spinal cord injury: A phase I/IIa 
clinical trial. Eur. Spine J. 21:2580–2587; 2012. 
Tator, C. H.; Fehlings, M. G. Review of the secondary 29. 
injury theory of acute spinal cord trauma with emphasis on 
vascular mechanisms. J. Neurosurg. 75:15–26; 1991.
